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she field of outcomes research continues to grow in its
ophistication, scope, and importance. Our ability to track
atterns of disease and health care and patient outcomes
ontinues to build on stronger methodological approaches,
dvances in computing technology, and the coordination of
alented investigators. Breakthroughs in the diagnosis and
reatment of cardiovascular disease are applying pressure on
he field to assess and enhance the translation of best
ractice into actual practice. Spiraling health care costs, as a
esult of expanding clinical capabilities and the aging of the
opulation, challenge clinicians and policymakers to develop
system that is effective and affordable. Practical research
hat can provide insight regarding clinical care and popula-
ion policies is needed now more than ever. Keeping pace
ith this research requires a survey of a broad range of
ublication venues in this truly multidisciplinary field.
This overview highlights information from prominent
pidemiology, health services, and outcomes research pub-
ications from April 2004 through March 2005. Because it
s not possible to include all the high-quality publications in
his topic area, I sought to feature those I consider to have
een particularly high-impact. Similar to last year’s review,
he studies included here are organized within categories
onsistent with the core goals for the future of American
ealth care, as articulated by the National Academy of
ciences Institute of Medicine (IOM)—safety, effective-
ess, equity, efficiency, timeliness, and patient-centeredness.
new category is included this year for policy-relevant
tudies of population trends and epidemiology.
AFETY
afety was a prominent topic in cardiovascular care this year.
everal studies revealed risks associated with common med-
cations, highlighting the need for the careful collection of
nformation about adverse events. Interest in safety and
afety-promotion strategies is likely to play an increasingly
trong role in the future of clinical care.
Studies of the risks associated with cyclooxygenase
COX)-2 inhibitors had tremendous impact. In a nested
ase-control study using data from Kaiser Permanente in
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Manuscript received June 5, 2005; accepted June 14, 2005.alifornia, Graham et al. (1) found that rofecoxib was
ssociated with higher risk of acute myocardial infarction
AMI) or sudden death compared with celecoxib. Juni et al.
2) published a cumulative meta-analysis in December
004, reporting that, even by the end of 2000, there was
vidence that rofecoxib, compared with placebo, more than
oubled a patient’s risk of an AMI. These observational
tudies were then supported by results from randomized
rials. In March 2005, Brasalier et al. (3) reported from the
denomatous Polyp Prevention on Vioxx (APPROVe)
rial that patients randomized to rofecoxib had nearly twice
he risk of a thrombotic event. Nussmeier et al. (4), in a trial
f valdecoxib and its intravenous prodrug parecoxib for pain
elief after bypass surgery, found that these drugs doubled
he risk of an important adverse event. Solomon et al. (5)
sed data from the Adenoma Prevention with Celecoxib
APC) trial and reported that celecoxib, compared with
lacebo, doubled the risk of cardiovascular events.
The growing use of statins drew several investigators to
xamine associated safety issues. Graham et al. (6) from the
ood and Drug Administration (FDA) made use of claims
ata from 11 U.S. managed care health plans to estimate the
ncidence of rhabdomyolysis in 252,460 patients treated
ith different statins and fibrates. With 225,640 person-
ears of monotherapy and 7,300 person-years of combined
herapy, the authors found 24 cases of incident rhabdomy-
lysis (16 with monotherapy and 8 with combined). This
tudy was able to put in perspective the absolute risk for
atients. The number-needed-to-treat for one year with
onotherapy to observe one case of rhabdomyolysis was
2,727 patients receiving atorvastatin, pravastatin, or sim-
astatin, and 3,546 patients for those receiving a fibrate.
trandberg et al. (7) addressed concerns that statins might
e linked to a cancer risk by examining the experience of the
candinavian Simvastatin Survival Study (4S). This ran-
omized trial included more than 4,000 patients age 35 to
0 years with previous AMI or angina pectoris, serum total
holesterol 5.5 to 8.0 mmol/l, and serum triglycerides 2.5
mol/l or lower (8). The investigators found that the
enefit of simvastatin persisted in a five-year post-trial
eriod. In addition, over 10 years of follow-up, simvastatin
as associated with a non-significant reduction in the risk of
ancer, allaying concerns.
Nesiritide, a potent vasodilator, attracted additional
afety concerns. Sackner-Bernstein et al. (9), in a meta-
nalysis of randomized, double-blind, controlled trials of
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ailure, reported that nesiritide increased the risk of wors-
ning renal function compared with non-inotrope and
notrope controls. In a separate systematic review, Sackner-
ernstein et al. (10) reported that nesiritide might be
ssociated with an increased risk of death, although a similar
nalysis by the FDA (11), using more data, failed to identify
he danger.
Unintended consequences of practice change after the
ublication of a randomized trial was the subject of a study
y Canadian investigators (12) who examined rates of
ospital stays for hyperkalemia after the release of the
andomized Aldactone Evaluation Study (RALES) (13),
hich showed that spironolactone, an aldosterone antago-
ist, was associated with a reduction in mortality and
orbidity for patients with severe heart failure. After the
ALES trial was published, the prescription rate for spi-
onolactone increased markedly, but so did the hospital-stay
ate for hyperkalemia. Interestingly, the increased use of
pironolactone prescription after the RALES trial was not
ssociated with a population-based improvement in heart
ailure outcomes.
Masoudi et al. (14) had previously reported that thiazo-
idinediones and metformin were prescribed commonly for
atients with heart failure and diabetes despite strong
arnings by the FDA against this practice. In a retrospec-
ive observational study of 16,417 Medicare beneficiaries
ospitalized with heart failure, they found that these med-
cations were actually associated with a lower risk of death at
ne year, but a slightly higher risk of readmission with
hiazolidinedione treatment (hazard ratio 1.06; 95% confi-
ence interval 1.00 to 1.09) (15). This finding leaves some
oubt about whether these drugs should be considered
ontraindicated for patients with heart failure.
Safety concerns surround not only the effects of the
edications but how they are prescribed. Growing enthu-
iasm for electronic health records can obscure the potential
isks inherent in computer systems. Investigators from the
niversity of Pennsylvania used qualitative and quantitative
ethods to investigate the possible role of computerized
hysician order entry systems in medical errors (16). They
etermined that this system facilitated 22 types of medica-
ion error risks, which were reportedly observed by a high
ercentage of house staff on an at-least-weekly basis.
FFECTIVENESS
everal studies addressed the effectiveness of interventions
o improve cardiovascular care and outcomes. Effectiveness
articularly implies the impact of strategies in real-world
ettings and includes efforts to assess and improve quality of
are.
Studies of the effectiveness of guideline-based strategies
re useful in testing whether their application in actual
ractice matches the results achieved in a clinical trial. In a
ational Medicare study, Masoudi et al. (17) investigated patterns of angiotensin-converting enzyme (ACE) inhibitor
se and its effectiveness, particularly in populations that
ere generally not represented in the trials. They found that
CE inhibitors were associated with a lower risk of mor-
ality, a benefit that was slightly less than that reported in
reviously published trials. Moreover, even though creati-
ine levels were the strongest predictors of use, the benefit
f ACE inhibitors appeared consistent across various strata
f renal function. That ACE inhibitors prescribed at dis-
harge did not replicate the trial result might be explained in
study by Butler et al. (18), who found that only about
wo-thirds of patients who were prescribed ACE inhibitors
t discharge were current users one year later.
Several studies sought to characterize the nature of the
elationship between volume and outcomes. This topic is
articularly important as organizations increasingly push for
olume standards. Epstein et al. used a large national claims
atabase to examine institutional volume standards for
ercutaneous coronary intervention that were promulgated
n the American College of Cardiology/American Heart
ssociation (ACC/AHA) guidelines (19,20). They found
hat, compared with institutions with 400 cases, those
ith 200 had worse outcomes; however, the group with
00 to 399 cases annually was indistinguishable from the
ighest volume hospitals. In contrast, Wu et al. (21) studied
ypass surgery in New York and reported that hospital and
urgeon volume were related to outcome over a broad range
f volume.
Many institutions are developing the capacity for percu-
aneous coronary intervention without onsite bypass surgery
acilities. Wennberg et al. (22) used Medicare claims data to
ompare outcomes at sites with and without bypass surgery
apability. After adjustment for case mix, there was no
ignificant difference in the short-term risk of mortality for
rimary/rescue intervention. For patients undergoing a
on-primary/non-rescue procedure, however, the mortality
ate at hospitals without bypass surgery capability was
ignificantly higher, a finding that was primarily the result of
he experience of hospitals that performed 50 Medicare
rocedures annually. A randomized trial by Wharton et al.
23) also provided evidence that primary angioplasty at a site
ithout bypass surgery capability can achieve results that are
imilar to those achieved by hospitals with such capacity.
The importance of the organizational factors in quality of
are was highlighted by a study in which Bradley et al. (24)
eported remarkable national hospital-level variation in the
se of beta-blockers after AMI. In investigating the rela-
ionship between quality improvement efforts and beta-
locker rates, they found that administrative support and
hysician leadership, rather than particular tools, were the
ost important factors associated with higher beta-blocker
ates. They conclude that a positive organizational environ-
ent is an essential factor for excellent clinical performance.
The promise of health information technology and elec-
ronic alerts was reinforced by a study of venous thrombosis
rophylaxis conducted at the Brigham and Women’s Hos-
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o usual care or an intervention group in which the respon-
ible physician was alerted to the patient’s risk of a venous
hrombosis. The alert increased the appropriate use of
rophylaxis and was associated with a significant reduction
n the risk of deep vein thrombosis or pulmonary embolism.
he study was remarkable because it showed both a process
nd outcome improvement from a relatively simple inter-
ention.
The relationship of continuing medical education (CME)
o quality of care was undermined by the findings of Patel et
l. (26) at Duke. Using a large Medicare database, their
tudy found no indication that states with CME require-
ents had better use of evidence-based therapies. More-
ver, there was no association between CME requirements
nd one-year mortality.
Quality of cardiopulmonary resuscitation efforts were the
ocus of a few high-impact studies this year. Abella et al.
27), in a prospective, observational study of 67 patients,
dentified a number of commonly occurring defects. Within
he first 5 min of each resuscitation effort, chest compres-
ions were too slow in 28% of the 30-s time segments and
oo shallow for 37%. In 61% of the segments, ventilation
ates were too high. Swedish investigators also examined the
uality of out-of-hospital resuscitation efforts in a prospec-
ive study of 176 patients (28). They too found problems in
he frequency and depth of compressions and substantial
eviance from the advanced cardiac life support guidelines.
hese troubling findings were in contrast to the report of an
mory program that tested a strategy to improve in-hospital
esuscitation outcomes. They employed education and re-
lacement of monophasic defibrillators with a combination
f manual biphasic defibrillators used in automatic external
efibrillator (AED) mode and AEDs in all outpatient
linics and chronic care units (29). After initiation of this
rogram, patients with an arrest from ventricular tachycar-
ia or fibrillation had their chances of surviving to hospital
ischarge increased 14-fold.
Several notable studies focused on improving the organi-
ation of care. Koren et al. (30) demonstrated that a
ipid-lowering disease management clinic in managed care
nd Veterans Administration settings was much more
uccessful than usual care in helping patients reach National
holesterol Education Program (NCEP) goals. Ho et al.
31) found that cardiology involvement with Veterans Ad-
inistration patients with coronary artery disease was asso-
iated with better cholesterol and blood pressure manage-
ent.
Disease management for patients with heart failure also
merged as a potentially important intervention. Galbreath
t al. (32) randomized 1,069 patients to a telephonic disease
anagement system conducted by CorSolutions Inc. (Rose-
ont, Illinois). The intervention group had a survival
enefit but no change in health care use. In assessing a
isease management program provided for 90 days to
igh-risk heart failure patients, Kimmelsteil et al. (33) sound that the intervention reduced hospital days related to
eart failure. Koelling (34) specifically studied the impact of
ischarge education for heart failure patients and reported
hat a one-hour teaching session reduced the risk of repeat
ospital stay or death. The costs in the intervention group
uring the subsequent six months were nearly $3,000 lower.
What we are likely to see in the future is an even greater
mphasis on programs of care that seek to optimize the
mpact of the best medical science. Insights generated by
edical research are insufficient without practical applica-
ion, and the science of application has lagged behind the
dvances in more basic medical disciplines. There is a
ealization that there needs to be a strong effort to appro-
riately apply what we know.
QUITY
any studies focusing on cardiovascular disease have ad-
ressed the issue of equity in our health care system. These
tudies are beginning to clarify where and how race/
thnicity, gender, and socioeconomic status might disad-
antage specific populations in the care they receive and the
utcomes they experience.
Several studies have advanced our understanding of how
isparities are mediated. Bradley et al. (35) showed that
acial differences in time to reperfusion of ST-segment
levation myocardial infarction (STEMI) patients, which
ere almost 20 min longer for black patients undergoing
rimary angioplasty, could be accounted for by the hospital
o which the patients were admitted. Bach et al. (36)
howed that black patients predominately receive care from
small number of doctors who, on average, have less
raining and certification than those who care for white
atients. Barnato et al. (37) examined evidence-based care
or AMI and found that observed racial differences were, in
arge part, explained by a hospital effect. Konety et al. (38)
emonstrated that black patients were more likely than
hite patients to undergo bypass surgery at hospitals with
he highest mortality rates. Voigt et al. (39), in a California
tudy, showed that black patients with a strong indication
or an implantable cardioverter-defibrillator were much less
ikely than white patients to receive one (odds ratio 0.19).
roeneveld et al. (40) reported that racial differences in
mplantable cardioverter-defibrillator use can, in part, be
ttributable to geographic variation. These articles suggest
hat racial differences in care might be importantly related to
here black patients receive care. Remedies must address
otential deficiencies in care at such institutions and ensure
hat these populations have access to high-quality providers.
Other studies examined outcomes by race. Using the
ociety for Thoracic Surgeons (STS) national cardiac data-
ase, Taylor et al. (41) compared the rate of in-hospital
dverse outcomes after valve replacement surgery in 3,137
lack patients and 46,249 white patients. The STS database
ontains detailed information about the patient and the
urgery that has been abstracted from the medical record.
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October 4, 2005:1362–70 Year in Epidemiology, Health Services, and Outcomes Researchlthough black patients did not have a higher adjusted risk
f in-hospital mortality compared with white patients, there
as an association with a higher risk of complications.
From a population perspective, evidence remains that
ace is strongly associated with mortality risk. Satcher et al.
42) reported that the black/white standardized mortality
atios show a disadvantage for blacks that has not changed
ubstantially since 1960. They project that 83,570 excess
eaths each year could be averted through elimination of the
acial mortality gap.
Disparities by education were brought to the forefront by
Lancet article in which Huisman et al. (43) analyzed
ortality data that were representative for Western Europe.
hey focused on the period from January 1, 1990, through
ecember 31, 1997, including 304,410 deaths and
1,030,032 person-years at risk. They classified low educa-
ional level as lower secondary education (9th grade) or
ower, and high educational level as higher secondary
ducation (10th grade) or above. Low educational level was
ommon, exceeding 70% in the population. For every
00,000 person-years at risk, there were 796 excess deaths in
he low educational group compared with the high group.
he total number of excess deaths was highest for cardio-
ascular deaths, with a difference of 315/100,000 person-
ears at risk, representing almost 40% of the difference in
otal mortality between the educational groups in men and
0% in women. The authors conclude that reduction of
ardiovascular mortality among groups at low educational
evels should be a particular priority for Western Europe; it
s likely that these finding are generalizable to other regions.
A number of studies of disparities focused on differences
n procedure rates. Cromwell et al. (44) added to this
iterature in a study using Medicare claims. They reported
hat white and Asian patients have higher rates of cardiac
atheterization and revascularization procedures after an
dmission for ischemic heart disease. Rathore and Krum-
olz (45), in an opinion piece, emphasized the importance
n such studies of understanding whether differences in rates
re associated with disparities in outcomes; that is, do the
escribed differences have consequence. These types of
nferences are difficult to discern without information about
he indications for the procedures. Without information
bout the appropriateness of the intervention, it is not
ossible to equate higher use with better care.
Interest in interventions to modify risk profiles in vulner-
ble populations has led to alternative models of care.
ecker et al. (46) compared community-based care with
enhanced” primary care to reduce heart disease risk in
igh-risk black families in Baltimore. They randomized
iblings of black patients 60 years of age who were
ospitalized for heart disease. The community-based care
as designed by a community advisory panel and provided
n a non-clinical site. In visits to these sites, a physical
ssessment, including blood pressure, was performed by a
urse practitioner, and education was provided by a com-
unity health worker. Enhanced primary care included Asual health care and education. Risk-reduction medications
ere covered for both groups. The 196 patients in the
ommunity-based group were twice as likely to reach blood
ressure and low-density lipoprotein goals than the 168
atients in the primary care group. The community group
as also much more likely to quit smoking. This rigorous
tudy shows remarkable improvement in risk reduction in a
ery high-risk population, and should open the possibility of
xpanding this model.
The bottom line of these studies is that disparities persist,
nd the goal of real equity in health care, although possible,
emains currently beyond our reach. The root causes might be
tructural and societal, and the necessary remedies will likely
ake the form of system reform and quality improvement—as
ell as addressing societal problems that lead to poor health
nd health outcomes.
FFICIENCY
ealth care costs remain a focus of many studies. Figures
end to lag, and the information for 2003 has just recently
ecome available. In aHealth Affairs article, Smith et al. (47)
eported that the growth in health care slowed in 2003 for
he first time in seven years; however, slow growth is growth
evertheless, and the national health spending still increased
.7% to reach $1.7 trillion, or $5,670/person. In 2003, the
.S. devoted 15.3% of its gross domestic product to health
are, an increase of 0.4% from 2002. Of note, prescription
rug sales rose 10.7% to $179.2 billion.
Cost issues have naturally raised interest in regional
ariation in the intensity of treatment and its relationship to
utcomes. Stukel et al. (48) investigated whether AMI
atients living in areas with more intensive invasive treat-
ent options had better outcomes. Cardiac catheterization
ates ranged from 29% to 93% across the 566 coronary
ngiography service areas. Among the regions with high use
f appropriate medical management, invasive management
as not associated with better survival. The authors con-
luded that routine use of more invasive treatment strategies
ight not be associated with an overall population benefit
eyond that seen with excellent medical management.
With increasing concerns about escalating health care
osts, choices about the allocation of scarce resources are
nder scrutiny. Several studies addressed the cost-
ffectiveness of specific strategies. Many reported that the
ore expensive strategies were a reasonable investment by
he usual standard of being below $50,000/year of life saved.
hether we can afford to implement all the strategies in
his range requires debate at the national level. For now,
everal of the studies described in the following section
rovide some perspective on the relationship of cost to
linical benefit.
Many studies specifically estimated cost-effectiveness ra-
ios for medical strategies. Weintraub et al. (49), in a study
ponsored by Pfizer, used data from the Eplerenone Post-
cute Myocardial Infarction Heart Failure Efficacy and
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ffectiveness of eplerenone compared with placebo in pa-
ients with left ventricular systolic dysfunction and heart
ailure after AMI. Using a daily cost of $3.60 for
plerenone, they estimated that the cost-effectiveness ratio
as $22,000/life-year gained, a ratio that would be
onsidered an economically attractive investment. Unfortu-
ately, the authors did not model how eplerenone would
ompare with spironolactone, a much less expensive aldo-
terone antagonist. If the favorable results in the EPHESUS
rial represent a class effect, it might be a more efficient
trategy to start with the less expensive option.
Weintraub et al. (50), in another industry-sponsored
tudy, employed data from the Clopidogrel in Unstable
ngina to prevent Recurrent Events (CURE) trial to deter-
ine the cost-effectiveness of clopidogrel, compared with
lacebo, up to one year after an acute coronary syndrome
ithout ST-segment elevation. The cost-effectiveness ratios
ere estimated to be$6,500/life-year gained. The authors
emonstrated that the strategy remained economically at-
ractive even if the life expectancy gain was just 20% of that
rojected from the trial or if the consequence of bleeding
as higher than their best estimates.
Clopidogrel was also the subject of a study that examined
he economic consequences of extending therapy after
ercutaneous coronary intervention from one month to one
ear (51). On the basis of randomized trial results, investi-
ators estimated that this additional therapy cost $879/
atient and reduced the risk of AMI by 2.6%. On the basis
f their projections, it was estimated that extending therapy
ad a cost-effectiveness ratio of $15,696/year of life saved.
Debate also continues about the role of bivalirudin versus
eparin. The Randomized Evaluation in PCI Linking
ngiomax to Reduced Clinical Events (REPLACE)-2
tudy found that bivalirudin with provisional glycoprotein
IB/IIIA inhibition was not inferior to heparin with routine
lycoprotein IIB/IIIA inhibition. In an industry-sponsored
tudy, Cohen et al. (52) found that the bivalirudin strategy
aved about $400/patient, owing mostly to a reduction in
leeding and thrombocytopenia.
Particular clinical strategies are also commonly the sub-
ect of these types of studies. For example, debates are
ngoing about whether STEMI patients should be diverted
o centers with primary angioplasty capabilities. The Com-
arison of Angioplasty and Pre-hospital Thrombolysis in
cute Myocardial Infarction (CAPTIM) trial, a European
tudy, showed that primary angioplasty and pre-hospital
brinolytic therapy with rescue angioplasty, as needed, had
imilar results at 30 days (53). The study included STEMI
atients who were within an hour of a percutaneous coro-
ary intervention center. Machecourt et al. (54) compared
he costs of these strategies, finding the fibrinolytic group to
e disadvantaged in that, even though they received medical
herapy first, 83% had coronary angiography during the
nitial hospital stay and 35% had rescue angioplasty. At one
ear, costs were slightly more than $1,000 lower in the troup randomized to primary angioplasty. It is currently
nknown if these results can be replicated in other settings.
Many cardiologists have adopted a transesophageal
chocardiography-guided strategy instead of a conventional
nticoagulation strategy for patients with atrial fibrillation of
2-days duration who are scheduled to undergo electrical
ardioversion. The best study of this approach was the
ssessment of Cardioversion Using Transesophageal Echo-
ardiography (ACUTE) trial that found, at eight weeks, the
wo strategies had comparable rates of death, maintenance
f sinus rhythm, and functional status (55). Klein et al. (56)
lso examined the relative costs of the strategies, because
onventional therapy was associated with longer time to
ardioversion and a higher risk of bleeding complications;
owever, considering the cost of the transesophageal echo-
ardiogram, total costs were not significantly different be-
ween the groups.
The costs of devices and procedures are also attracting a
hare of attention. Studies have shown that there is embolic
rotection for patients undergoing percutaneous interven-
ion of saphenous vein bypass grafts. On the basis of data
rom the Saphenous Vein Graft Angioplasty Free of Emboli
andomized (SAFER) trial (57), investigators conducted
n industry-sponsored economic analysis of the GuideWire
alloon occlusion device. Cohen et al. (58) estimated that
he lifetime cost-effectiveness ratio for the protection device
as $3,718/year of life gained.
The Mode Selection in Sinus Node Dysfunction Trial
MOST) showed that dual-chamber pacing was associated
ith a lower rate of atrial fibrillation and subsequent
ospital stay for heart failure than single chamber pacing
59). Rinfret et al. (60) sought to determine whether the
uality-of-life advantage of dual-chamber pacing was eco-
omically attractive. The mean age of the patients in the
rial was 74 years. They estimated that, during the course of
patient’s lifetime, the dual chamber pacemaker increased
uality-adjusted life expectancy by 0.14 years, with a cost-
ffectiveness ratio of $6,800/quality-adjusted year of life
ained.
The Bypass Angioplasty Revascularization Investigation
BARI) showed that bypass surgery and angioplasty
chieved similar results (61). Long-term follow-up infor-
ation is now available, and the BARI study investigators
ave examined costs and quality-of-life outcomes at 10 to
2 years after randomization (62). Initially, patients in the
ypass surgery arm had greater improvement in physical
unction, but that advantage narrowed over time and was
ot significant by four years. Bypass surgery was initially
ore expensive, but by 12 years the costs were virtually
dentical. Over 12 years, percutaneous transluminal coro-
ary angioplasty patients accrued a mean of 8.42 life-years
f survival compared with 8.58 life-years for bypass surgery
atients. At 12 years, the cost-effectiveness of bypass surgery
as $14,300/life-year.
Overall, these studies help quantify the resources requiredo produce a benefit. Very few studies reveal strategies that
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enefit to the patient. How we will afford all of the
trategies with favorable cost-effectiveness ratios is yet to be
etermined.
IMELINESS
n important goal of the health care system is timeliness
nd appropriate access to care. This issue has recently
eceived substantial emphasis with respect to time to reper-
usion for STEMI. The ACC/AHA STEMI guidelines
mphasized the importance of timely treatment and set
argets of 30 min after hospital presentation for the provi-
ion of fibrinolytic therapy and 90 min for primary angio-
lasty (63). These targets were informed by the work of
allamothu et al. (64), who examined the results of trials of
brinolytic therapy and angioplasty and found that the
ifference between the therapies was related to the differ-
nce in time to provision of therapy. When the time to
eperfusion was similar between the two strategies, then
rimary angioplasty was clearly superior; however, when
rimary angioplasty required about an hour longer to
rovide than fibrinolytic therapy, the two strategies yielded
imilar results.
Nallamothu et al. (65) also looked at the total time to
eperfusion, for STEMI patients transferred from one
ospital to another to undergo primary angioplasty, a
eglected time interval. The authors examined 4,278 trans-
er patients with STEMI who underwent primary percuta-
eous coronary intervention at 419 hospitals included in the
ational Registry of Myocardial Infarction database. The
edian time from the initial hospital arrival to the first
alloon inflation at the receiving hospital was 180 min. Only
6% of the patients had a total door to balloon time 2 h,
nd 5% had a door to balloon time of 90 min, the
uideline standard.
ATIENT-CENTEREDNESS
here continues to be strong interest in assessing a wide
ange of outcomes from the patient’s perspective, with
articular interest in health status and quality of life. Many
tudies are incorporating these outcomes into their patient
ssessments.
One such example is the third Randomized Intervention
rial of unstable Angina (RITA-3), which compared an
arly interventional strategy (IS) with a conservative strategy
CS) in the treatment of patients with unstable angina or
on-STEMI (66). After one year, the treatment groups had
imilar rates of the combined end point of death or nonfatal
MI. The investigators added to the trial results by com-
aring quality-of-life outcomes and reported IS to be
ssociated with greater improvements in quality of life,
rincipally because of its effect on angina burden (67).
Another contribution by Spertus et al. (68) addressed the
ymptom outcomes of patients undergoing percutaneous
oronary intervention. Their observational study demon- itrated that although many patients experienced a quality-
f-life benefit, 13% of the patients with no angina at the
ime of the procedure had worse quality of life one year later.
he strongest predictors of quality-of-life improvement at
ne year were baseline functional status and angina burden.
OPULATION TRENDS AND EPIDEMIOLOGY
any studies have focused on recent trends in cardiovascu-
ar risk factors and disease. In a notable publication, Fra-
ingham Heart study investigators examined heart disease
ortality and sudden death from 1950 to 1999 (69). In this
eriod, overall coronary heart disease deaths decreased by
9%, and sudden death decreased by 49%, consistent in men
nd women. These estimates should be considered fairly
eliable and better than studies based on death certificates
ecause, in Framingham, each event is adjudicated.
Although the U.S. has been experiencing a decline in
ardiovascular disease, there is evidence that other countries
re undergoing an epidemiologic transition. In China,
etween 1984 and 1999, Critchley et al. (70) reported that
oronary heart disease mortality rates increased by 50% in
en and 27% in women. They further determined that
ising cholesterol levels and the prevalence of obesity and
iabetes accounted for 77% of the additional deaths. The
otential consequences of an epidemic of vascular disease in
hina cannot be overestimated.
There are also indications that progress by the U.S. in
educing heart disease could be in jeopardy on the basis of
eports of cardiovascular risk factors in young people. Using
he Third National Health and Nutrition Examination
urvey (NHANES) 1988 to 1994, de Ferranti et al. (71)
ound that two-thirds of the surveyed adolescents (age 12 to
9 years) had at least one metabolic abnormality and 10%
ad metabolic syndrome. Ford et al. (72), using data from
988 to 1994 and 1999 to 2000, found temporal increases in
aist circumference (2 cm) and systolic blood pressure
about 2 mm Hg). Hedley et al. (73) reported that in 2001
o 2002, the prevalence of overweight (85th to 94th per-
entile) among children age 6 through 19 years was 31.5%
nd obesity (95th percentile) was 16.5%.
Heart failure is also the focus of considerable work. Roger
t al. (74) studied trends in Olmsted County, Minnesota, as
art of the Rochester Epidemiology Project. They found
hat the incidence of heart failure in men and women did
ot change substantially over the periods 1979 to 1984,
985 to 1990, 1991 to 1995, and 1996 to 2000. Among
atients with heart failure, the risk of mortality over five
ears decreased from 57% in 1979 to 1984 to 48% in 1996
o 2000. Younger men experienced the greatest gain in
urvival.
Koelling et al. (75), using the National Hospital Dis-
harge Survey, examined trends in heart failure hospital
tays. They estimated that by 2000 there were more than 1
illion heart failure hospital stays yearly in the U.S., anncrease from approximately 800,000 at the beginning of the
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en but increased steadily for women.
Substantial attention has been placed on the epidemic of
besity. Daviglus et al. (76) investigated how body mass
ndex in midlife affects long-term risk and health care
esource consumption. They used data from the Chicago
eart Association Detection Project in Industry (CHA)
1967 to 1973) for 9,978 men (mean age, 46.0 years) and
,623 women (mean age, 48.4 years) and tracked their
ong-term health care outcomes using Medicare data. They
eported that people who are overweight and obese in
iddle age consume substantially more health care re-
ources in old age.
With attention on obesity, Dansinger et al. (77) com-
ared four popular diets (Atkins, Zone, Weight Watchers,
nd Ornish) for weight loss and cardiac risk-factor reduc-
ion. Participants had lost approximately 3 kg at one year,
nd no significant differences were found between the diets.
he change in cardiovascular risk factors was also similar.
eanwhile, Knoops et al. (78) made use of a 10-year
ollow-up of the Healthy Ageing: a Longitudinal study in
urope (HALE) population and investigated the effect of
dhering to a Mediterranean diet and a healthy lifestyle.
he Mediterranean diet was associated with a 23% lower
isk of mortality. Moderate alcohol consumption, physical
ctivity, and nonsmoking were also associated with substan-
ially lower risks of mortality, heart disease, and cancer.
One of the most remarkable contributions this year was a
ase-control study of AMI across 52 countries, in which
usuf et al. (79) investigated the importance of cardiovas-
ular risk factors. Despite the increased attention that has
een focused on new risk factors, they found that standard,
raditional risk factors accounted for most of the risk of
MI. These factors included abnormal lipids, smoking,
ypertension, diabetes, abdominal obesity, psychosocial fac-
ors, consumption of fruits, vegetables, and alcohol, and
hysical activity. The population-attributable risk for these
actors was 90%. The finding suggests that public health
fforts should focus on currently known risk factors and that
odification of these factors has the potential to prevent
ost cases of AMI.
ONCLUSIONS
his year was another remarkably productive period for
rticles relevant to improving health and health care deliv-
ry. These studies, which represent only a sample of the
ighlights of the year, generate knowledge that can imme-
iately be incorporated into practice and policy as we seek to
nsure that patients and populations have every opportunity
o achieve the best possible outcomes. The field will seek,
ncreasingly, to provide insight about our achievements and
hortfalls—and to strive to contribute to the positive evo-
ution of the health care system by providing a scientific
asis for clinical practice and system improvement.eprint requests and correspondence:Dr. Harlan M. Krumholz,
ale University School of Medicine, 333 Cedar Street, P.O. Box
08088, New Haven, Connecticut 06520-8088. E-mail: harlan.
rumholz@yale.edu.
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